Patent assignee · CA · COMPANY

Biomira, Inc.

17Patents
0Active
17Granted
32Portfolio score

Filing activity: Feb 1, 1988 → Nov 7, 2001

Most-cited patents

PatentTitleAreaCited byStatus
US5110911A Human tumor-associated Thomsen-Friedenreich antigen Emerging Cross-Sectional Technologies 52 Expired
US6600012B1 Lipid-modified muc-1 derivatives Emerging Cross-Sectional Technologies 26 Expired
US6013779A Process for preparation of glycosides of tumor-associated carbohydrate antigens Chemistry; Metallurgy 19 Expired
US5075218A Screening for antibodies which bind carbohydrate epitopes of tumor-associated antigens, and uses thereof Emerging Cross-Sectional Technologies 16 Expired
US5055562A Fluorocarbon chain-containing antigenic conjugates Human Necessities 14 Expired
US5242799A Lectin-antibody immunoassays for TF epitope-bearing antigens Emerging Cross-Sectional Technologies 10 Expired
US5798090A Enhancement of the cellular immune response Human Necessities 8 Expired
USRE38046E1 Enhancement of the cellular immune response General 7 Expired
US4935503A Azidochlorination and diazidization of glycals Chemistry; Metallurgy 6 Expired
US7491707B1 Synthetic lipid-a-analogs and uses thereof Emerging Cross-Sectional Technologies 6 Expired
US4971795A Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype Human Necessities 5 Expired
US6114129A Methods of detecting T-cell activation and treating disorders associated with T-cell dysfunction Physics 3 Expired
US5527891A Stereodirected process for synthesis of .alpha.-N-acetylgalactosaminides Emerging Cross-Sectional Technologies 2 Expired
US5837830A Stereodirected process for synthesis of .alpha.-N-acetylgalactosaminides Emerging Cross-Sectional Technologies 1 Expired
US5455332A Carcinoma-marking monoclonal antibodies elicited with synthetic Asialo-GM1 antigen Chemistry; Metallurgy 1 Expired
US6582697B2 Enhancement of the cellular immune response Human Necessities 0 Expired
US6326009A Enhancement of the cellular immune response Human Necessities 0 Expired

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.